keyword
MENU ▼
Read by QxMD icon Read
search

Dronabinol

keyword
https://www.readbyqxmd.com/read/29745439/cannabinoids-and-gastrointestinal-motility-pharmacology-clinical-effects-and-potential-therapeutics-in-humans
#1
REVIEW
M Camilleri
BACKGROUND: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. PURPOSE: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity...
May 10, 2018: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/29689485/the-effect-of-high-dose-dronabinol-oral-thc-maintenance-on-cannabis-self-administration
#2
Nicolas J Schlienz, Dustin C Lee, Maxine L Stitzer, Ryan Vandrey
BACKGROUND: There is a clear need for advancing the treatment of cannabis use disorders. Prior research has demonstrated that dronabinol (oral THC) can dose-dependently suppress cannabis withdrawal and reduce the acute effects of smoked cannabis. The present study was conducted to evaluate whether high-dose dronabinol could reduce cannabis self-administration among daily users. METHODS: Non-treatment seeking daily cannabis users (N = 13) completed a residential within-subjects crossover study and were administered placebo, low-dose dronabinol (120 mg/day; 40 mg tid), or high-dose dronabinol (180-240 mg/day; 60-80 mg tid) for 12 consecutive days (order counterbalanced)...
April 17, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29670357/dronabinol-oral-solution-in-the-management-of-anorexia-and-weight-loss-in-aids-and-cancer
#3
REVIEW
Melissa E Badowski, Paa Kwesi Yanful
The true incidence of anorexia secondary to human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and cancer is not well classified owing to the fact that there is a lack of standardized definitions and recent clinical data in these settings. Dronabinol, or Δ-9-tetrahydrocannabinol, is a synthetic molecule that closely mimics the action of Cannabis sativa L., a naturally occurring compound activated in the central nervous system by cannabinoid receptors. Dronabinol exerts its effects by directly acting on the vomiting and appetite control centers in the brain, which in turn increases appetite and prevents vomiting...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29609727/medical-cannabis-and-the-treatment-of-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-position-statement
#4
Kannan Ramar, Ilene M Rosen, Douglas B Kirsch, Ronald D Chervin, Kelly A Carden, R Nisha Aurora, David A Kristo, Raman K Malhotra, Jennifer L Martin, Eric J Olson, Carol L Rosen, James A Rowley
The diagnosis and effective treatment of obstructive sleep apnea (OSA) in adults is an urgent health priority. Positive airway pressure (PAP) therapy remains the most effective treatment for OSA, although other treatment options continue to be explored. Limited evidence citing small pilot or proof of concept studies suggest that the synthetic medical cannabis extract dronabinol may improve respiratory stability and provide benefit to treat OSA. However, side effects such as somnolence related to treatment were reported in most patients, and the long-term effects on other sleep quality measures, tolerability, and safety are still unknown...
March 30, 2018: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/29516114/-acute-emergencies-in-oncology
#5
REVIEW
D Nashan, S Dengler
The spectrum of dermato-oncological emergencies is multifaceted. They are particularly observed in cases with malignant melanoma due to the large number of patients and prolonged survival rates that are associated with new therapies for advanced disease. Dermato-oncological patients present to the hospital with symptoms like nausea and emesis, unexpected neurological deficits, various gastrointestinal problems, and even acute abdomen, acute breathlessness, or hemoptysis. Furthermore, emergencies can be caused by hematological problems like anemia and leukopenia...
May 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29513392/cannabis-based-medicines-for-chronic-neuropathic-pain-in-adults
#6
REVIEW
Martin Mücke, Tudor Phillips, Lukas Radbruch, Frank Petzke, Winfried Häuser
BACKGROUND: This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms of action for treatment of conditions with chronic neuropathic pain...
March 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29457671/abstinence-and-reduced-frequency-of-use-are-associated-with-improvements-in-quality-of-life-among-treatment-seekers-with-cannabis-use-disorder
#7
Christina A Brezing, C Jean Choi, Martina Pavlicova, Daniel Brooks, Amy L Mahony, John J Mariani, Frances R Levin
BACKGROUND AND OBJECTIVE: Many patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD...
March 2018: American Journal on Addictions
https://www.readbyqxmd.com/read/29442178/the-use-of-cannabis-and-cannabinoids-in-treating-symptoms-of-multiple-sclerosis-a-systematic-review-of-reviews
#8
REVIEW
Suzanne Nielsen, Rada Germanos, Megan Weier, John Pollard, Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Michael Farrell
PURPOSE OF REVIEW: Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects...
February 13, 2018: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/29400010/systematic-review-and-meta-analysis-of-cannabinoids-in-palliative-medicine
#9
REVIEW
Martin Mücke, Megan Weier, Christopher Carter, Jan Copeland, Louisa Degenhardt, Henning Cuhls, Lukas Radbruch, Winfried Häuser, Rupert Conrad
We provide a systematic review and meta-analysis on the efficacy, tolerability, and safety of cannabinoids in palliative medicine. The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO, PubMed, Scopus, and http://clinicaltrials.gov, and a selection of cancer journals were searched up until 15th of March 2017. Of the 108 screened studies, nine studies with a total of 1561 participants were included. Overall, the nine studies were at moderate risk of bias. The quality of evidence comparing cannabinoids with placebo was rated according to Grading of Recommendations Assessment, Development, and Evaluation as low or very low because of indirectness, imprecision, and potential reporting bias...
April 2018: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/29232070/schedules-of-controlled-substances-placement-of-fda-approved-products-of-oral-solutions-containing-dronabinol-delta-9-trans-tetrahydrocannabinol-delta-9-thc-in-schedule-ii-final-rule
#10
(no author information available yet)
This final rule adopts without changes an interim final rule with request for comments published in the Federal Register on March 23, 2017. On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug product consisting of dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] oral solution. The Drug Enforcement Administration (DEA) maintains FDA-approved products of oral solutions containing dronabinol in schedule II of the Controlled Substances Act...
November 22, 2017: Federal Register
https://www.readbyqxmd.com/read/29197104/the-effect-of-dronabinol-in-a-male-patient-with-anorexia-nervosa-suffering-from-severe-acute-urge-to-be-physically-active
#11
Holmer Graap, Yesim Erim, Georgios Paslakis
OBJECTIVE: A 27-year-old male suffering from chronic anorexia nervosa was admitted for inpatient psychotherapy suffering from severe urge to be physically active. METHODS: An off-label treatment with dronabinol was initiated, to reduce his symptoms related to that urge. Several attempts to reduce symptoms including intensive psychotherapy and several psychopharmacological agents had failed in the past. RESULTS: Following treatment with 7.5 mg dronabinol twice a day, the patient reported a significant reduction in his acute urge to be physically active...
February 2018: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/29134767/availability-and-approval-of-cannabis-based-medicines-for-chronic-pain-management-and-palliative-supportive-care-in-europe-a-survey-of-the-status-in-the-chapters-of-the-european-pain-federation
#12
N Krcevski-Skvarc, C Wells, W Häuser
BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care...
March 2018: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29121334/pharmacotherapy-of-apnea-by-cannabimimetic-enhancement-the-pace-clinical-trial-effects-of-dronabinol-in-obstructive-sleep-apnea
#13
David W Carley, Bharati Prasad, Kathryn J Reid, Roneil Malkani, Hryar Attarian, Sabra M Abbott, Boris Vern, Hui Xie, Chengbo Yuan, Phyllis C Zee
Study Objectives: There remains an important and unmet need for fully effective and acceptable treatments in obstructive sleep apnea (OSA). At present, there are no approved drug treatments. Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study. Here, we present initial findings of the Phase II PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial, a fully blinded parallel groups, placebo-controlled randomized trial of dronabinol in people with moderate or severe OSA...
January 1, 2018: Sleep
https://www.readbyqxmd.com/read/29073592/dronabinol-is-a-safe-long-term-treatment-option-for-neuropathic-pain-patients
#14
Sebastian Schimrigk, Martin Marziniak, Christine Neubauer, Eva Maria Kugler, Gudrun Werner, Dimitri Abramov-Sommariva
Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis is still rarely offered for treatment of pain. This clinical trial aimed at showing the positive benefit-risk ratio of dronabinol. Two hundred forty MS patients with central NP entered a 16-weeks placebo-controlled phase-III study followed by a 32-weeks open-label period. One hundred patients continued therapy for overall up to 119 weeks. Primary endpoint was change of pain intensity on the 11-point Numerical Rating Scale over a 16-weeks treatment period...
2017: European Neurology
https://www.readbyqxmd.com/read/29066964/using-functional-near-infrared-spectroscopy-to-measure-effects-of-delta-9-tetrahydrocannabinol-on-prefrontal-activity-and-working-memory-in-cannabis-users
#15
Hasan O Keles, Milena Radoman, Gladys N Pachas, A Eden Evins, Jodi M Gilman
Intoxication from cannabis impairs cognitive performance, in part due to the effects of Δ9-tetrahydrocannabinol (THC, the primary psychoactive compound in cannabis) on prefrontal cortex (PFC) function. However, a relationship between impairment in cognitive functioning with THC administration and THC-induced change in hemodynamic response has not been demonstrated. We explored the feasibility of using functional near-infrared spectroscopy (fNIRS) to examine the functional changes of the human PFC associated with cannabis intoxication and cognitive impairment...
2017: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/29035934/dextrometorphan-paroxetine-but-not-dronabinol-effective-for-treatment-resistant-aggression-and-agitation-in-an-elderly-patient-with-lewy-body-dementia
#16
Robert Wilhelm, Björn Ahl, Ion-George Anghelescu
No abstract text is available yet for this article.
October 13, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29017688/cannabinoids-in-pain-management-and-palliative-medicine
#17
Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke
BACKGROUND: There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. METHODS: We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, and Medline...
September 22, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28934522/effects-of-cannabinoid-agonists-and-antagonists-on-sleep-and-breathing-in-sprague-dawley-rats
#18
Michael W Calik, David W Carley
Study Objectives: There are no pharmacological treatments for obstructive sleep apnea syndrome, but dronabinol showed promise in a small pilot study. In anesthetized rats, dronabinol attenuates reflex apnea via activation of cannabinoid (CB) receptors located on vagal afferents; an effect blocked by cannabinoid type 1 (CB1) and/or type 2 (CB2) receptor antagonists. Here, using a natural model of central sleep apnea, we examine the effects of dronabinol, alone and in combination with selective antagonists in conscious rats chronically instrumented to stage sleep and measure cessation of breathing...
September 1, 2017: Sleep
https://www.readbyqxmd.com/read/28796166/speechlessness-in-gilles-de-la-tourette-syndrome-cannabis-based-medicines-improve-severe-vocal-blocking-tics-in-two-patients
#19
Ewgeni Jakubovski, Kirsten Müller-Vahl
We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 × 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated...
August 10, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#20
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
September 2017: Cancer Chemotherapy and Pharmacology
keyword
keyword
36767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"